Cargando…
AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA
Glioblastoma (GBM) is the most common malignant brain tumor in adults, with a poor prognosis despite aggressive standard of care. Chimeric antigen receptor T-cell (CAR-T) therapy has shown promising results in liquid malignancies, but clinical trials in GBM targeting various tumor antigens have not...
Autores principales: | Salim, Sabra K, Shaikh, Vaseem, Maich, William T, Anand, Alisha, Brakel, Benjamin, Wei, Jeffrey, Subapanditha, Minomi K, Alizada, Zahra, Suk, Yujin, Singh, Manoj, Dimitrov, Vassil, Tabunshchyk, Zoya, Chen, Katie, Vora, Parvez, Venugopal, Chitra, Moffat, Jason, Singh, Sheila K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337548/ http://dx.doi.org/10.1093/noajnl/vdad071.024 |
Ejemplares similares
-
SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023) -
ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023) -
Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
por: Tatari, Nazanin, et al.
Publicado: (2020) -
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022) -
Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors
por: Tatari, Nazanin, et al.
Publicado: (2022)